Faculty Recruitment in Noida Institute of Pharmacy
The college runs B. Pharm & D. Pharm course started from 2018, also runs B. Tech, B. Sc and other courses.
Roche announced that it presented the latest results from three Phase III studies from the Tecentriq® (atezolizumab) clinical development programme in triple-negative breast cancer (TNBC) at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.
“While we have made great progress in the treatment of many forms of breast cancer, TNBC remains an aggressive and difficult-to-treat disease,” said Levi Garraway, M.D., Ph.D., Roche's Chief Medical Officer and Head of Global Product Development. “We are proud of our work to address challenges and advance scientific understanding of cancer immunotherapy in the context of distinct chemotherapy regimens and in various TNBC treatment settings. Although the IMpassion131 study did not reach its endpoint, we are pleased to bring new treatment options for some TNBC patients, and remain committed to improving the lives of all women with early and advanced stages of this disease.”
Results from the Phase III IMpassion031 study, evaluating Tecentriq in combination with chemotherapy (Abraxane®, albumin-bound paclitaxel; nab-paclitaxel; followed by doxorubicin and cyclophosphamide) in comparison to placebo plus chemotherapy (including nab-paclitaxel), demonstrated a statistically significant and clinically meaningful improvement in pathological complete response (pCR) for the treatment of people with early TNBC, regardless of PD-L1 expression. pCR was observed in 57.6% (95% CI: 49.7–65.2) of patients treated with Tecentriq in combination with chemotherapy, an increase of 16.5% from 41.1% (95% CI: 33.6–48.9) in patients treated with placebo plus chemotherapy (one-sided p=0.0044, significance boundary = 0.0184) in the intention-to-treat (ITT) population. The safety profile was consistent with the established profile of the individual drugs and no new safety concerns were identified.
The IMpassion031 study is the second positive Phase III study from Roche demonstrating the benefit of Tecentriq in TNBC, and the first Tecentriq study to demonstrate benefit in early TNBC. Tecentriq in combination with nab-paclitaxel is currently approved in more than 70 countries worldwide, including the US and across Europe, for the treatment of adults with unresectable locally advanced or metastatic TNBC in people whose tumours express PD-L1 (IC≥1%).
The final overall survival (OS) analysis of the Phase III IMpassion130 study, evaluating Tecentriq in combination with nab-paclitaxel, compared with placebo plus nab-paclitaxel, as a first-line treatment for patients with metastatic TNBC, was consistent with the first and second interim analyses. There was no significant difference in OS between the treatment groups in the ITT population. Clinically meaningful improvements in OS were seen with Tecentriq plus nab-paclitaxel in PD-L1-positive patients. The magnitude of OS improvements with Tecentriq in PD-L1-positive patients remained clinically meaningful, with an increase of 7.5 months in median OS with Tecentriq plus nab-paclitaxel, compared with placebo plus nab-paclitaxel (hazard ratio [HR]=0.67; 95% CI: 0.53–0.86). However, this result could not be formally tested due to the prespecified statistical testing hierarchy. The cumulative safety of the Tecentriq plus nab-paclitaxel combination remains consistent with the previously reported safety data for this study and the known risks of individual study drugs. No new safety concerns were identified with longer follow-up.
Finally, results from the Phase III IMpassion131 study, evaluating Tecentriq in combination with paclitaxel, compared with placebo plus paclitaxel, as a first-line treatment for patients with metastatic TNBC, did not show significant improvement for progression-free survival in the PD-L1-positive population (HR=0.82; 95% CI: 0.60–1.12). The OS data showed a negative trend; however, the study was not powered for the secondary endpoint of OS, and OS data were immature at time of analysis (initial HR=1.55 [95% CI: 0.86-2.80] in the PD-L1 positive population, based on 21% of patients with an event; updated HR=1.12 [95% CI: 0.76-1.65]), updated analysis based on 41% of patients with an event). The safety profile of Tecentriq plus paclitaxel was consistent with the established safety profile of the individual study drugs and no new safety concerns were identified.
Roche has an extensive development programme for Tecentriq, including multiple ongoing and planned Phase III studies across several types of lung, genitourinary, skin, breast, gastrointestinal, gynaecological and head and neck cancers. This includes studies evaluating Tecentriq both alone and in combination with other medicines.
The fight against Typhoid fever is all set to get a major fillip with a team of scientists led by Dr. Amit Kumar from Indian Institute of Technology (IIT)-Indore, finding new ways to tackle Salmonella enterica, the pathogenic bacterium that causes the fever.
“Ministry of AYUSH, Govt. of India suggested the use of homeopathic medicine Arsenicum album - 30 for its possible role in preventing COVID-19 infection”said Dr. Anil Khurana, Director General, Central Council for Research in Homoeopathy.
PHD Chamber with South Delhi Homoeopathic Association (SDHA) organized 28th Annual Homoeopathic Conference, Kent Memorial Lectures 2020, Inaugural Session held on 19th September 2020.
The eminent panellists present were Dr. Anil Khurana, Director General, Central Council for Research in Homoeopathy, Dr. R. K. Manchanda, Director AYUSH, Govt. of NCT. of Delhi, Mr. Arvind Varchaswi, Chairman, AYUSH Committee, Mr. Vivek Seigell, Principal Director, PHDCCI, Dr. R.N. Wahi, Chairman, Organising Committee, SDHA, Dr. Satya Vir Sharma, Director (Finance), SDHA.
Dr. Anil Khurana, Director General, Central Council for Research in Homoeopathy talked about success story about homoeopathy treating and managing the symptoms for Chikungunya and Dengue in the past years. Dr. Khurana said that Homoeopathy have played a significant role in providing treatment in active conditions. He mentioned, that Ministry of AYUSH, Govt. of India have taken various steps and CCRH council is working on various scientific research and clinical trials are in progress during COVID-19 period. He also shared about the latest guidelines launched by the Ministry for Tele- Medicine for all homoeopathy physcians, while imparting tele consultation to the patients.
Dr. Khurana said that these guidelines contain information and advisories, which could play an important role in the management of COVID19 pandemic. He also talked about the AYUSH Sanjivani app to generate data on usage of AYUSH (Ayurveda, Yoga & Naturopathy, Unani, Siddha, Sowa-rigpa and Homoeopathy) advocacies and measures among the population and its impact in prevention of Covid-19.He mentioned that Ministry of AYUSH, Govt. of India have suggested the use of Arsenicum album - 30 for its possible role in preventing COVID-19 infection.
Dr. R. K. Manchanda, Director AYUSH, Govt. of NCT. of Delhi shared a brief presentation about the opportunities for Homoeopathic Associations. Dr. Manchanda mentioned about emerging of global scenario during COVID-19 period. He also shared about ongoing challenges faced by homoeopaths. He also mentioned about Increasing public demand and presence of homeopathy in various countries. He also talked about the efforts been made for prevention and treatment of COVID-19 patients by Homoeopathic physicians in all over India. He also urged all Associations should focus on high quality research oriented communications and should also be part of global movements.
Mr. Arvind Varchaswi, Chairman, AYUSH Committee talked about how to focus on an individual immunity by maintaing a balance lifestyle and personal hygiene during ongoing pandemic. He also talked about the benefits of Yoga, Meditation and stretching exercises for maintaing a healthy lifestyle.
He also mentioned about Immunomodulators availability for boosting immunity during these challenging times. He said Homoeopathy is a system of medicine, which is also well recognized in Europe and USA and other parts of countries as well.
Mr. Vivek Seigell, Principal Director, PHDCCI talked about the Indian system of medicine and benefits of Homoepathy. He also urged homoepathic physician to come forward and promote the system of homoepathy. He also mentioned that associations should collaborate & work together for promoting the entire system and take PHD Chamber’s platform for promoting homoeopathy as a strong system of medicine.
Dr. R.N. Wahi, Chairman, Organising Committee in his opening remarks thanked all the panellist for joining 28th Annual Homoepathic conference. Dr. Wahi talked about the role and significane of homeopathy. He further added that there’s a utmost need for involvement of new technology and scientific research into the system.
Dr. Satya Vir Sharma, Director (Finance), SDHA thanked all the panellist and homoeopathy physicians for sparing their valuable time in joining today’s conference. He said the two days technical sessions with the experts will certainly uplift the system of homoeopathy medicine and morale of all physicians attending the conference.
The Inaugural session for 28th Annual Homoeopathic Conference, Kent Memorial Lectures 2020 was attended by over 120 homoeopathy physicians and medical practitioners.
RECOMMENDED POSTS
Subscribe with us
Do Not Forget to Verify
(Click on Subscription link in your inbox)
--------
Also Join: 
.png)
